NorthStar Medical Radioisotopes, LLC

At NorthStar Medical Radioisotopes, our mission is to provide patients global access to game-changing radiopharmaceuticals. We are a growing, commercialized nuclear medicine company focused on advancing patient care by providing diagnostic and therapeutic radioisotopes, novel radiopharmaceuticals and customized radiopharmaceutical development services. NorthStar is the only commercial U.S. producer of the important diagnostic imaging radioisotope molybdenum-99 (Mo-99). Our FDA-approved RadioGenix® System (technetium Tc 99m generator) uses U.S.-produced, non-uranium based Mo-99 as source material to generate technetium-99m (Tc-99m), used to assess heart disease and cancer for 40,000 U.S. patients daily. NorthStar continues to expand Mo-99 production capabilities to meet anticipated increased demand.